We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+8.75%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.69B
AUM Growth
-$542M
Cap. Flow
-$781M
Cap. Flow %
-21.18%
Top 10 Hldgs %
56.86%
Holding
480
New
156
Increased
61
Reduced
86
Closed
113

Top Buys

Rank Stock Value
1
SKX
Skechers
SKX
+$207M
2
BPMC
Blueprint Medicines
BPMC
+$176M
3
WBA
Walgreens Boots Alliance
WBA
+$167M
4
DNB
Dun & Bradstreet
DNB
+$122M
5
INFA
Informatica
INFA
+$93.8M

Top Sells

Rank Stock Value
1
DFS
Discover Financial Services
DFS
+$408M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$408M
3
HES
Hess
HES
+$251M
4
BECN
Beacon Roofing Supply, Inc.
BECN
+$195M
5
BERY
Berry Global Group, Inc.
BERY
+$137M

Sector Composition

Rank Sector Weight
1 Healthcare 19.77%
2 Technology 14.28%
3 Consumer Staples 10.98%
4 Energy 9.87%
5 Consumer Discretionary 9.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NI icon
426
NiSource
NI
$19.8B
– –
-277,340
Closed -$11.1M
NKTR icon
427
Nektar Therapeutics
NKTR
$2.53B
– –
-1,328
Closed -$13.5K
ONON icon
428
On Holding
ONON
$9.35B
– –
-50,000
Closed -$2.2M
OXY icon
429
PUT
Occidental Petroleum
OXY
$60B
– –
-90,000
Closed -$24.6K
PEPG icon
430
PepGen
PEPG
$215M
– –
-26,559
Closed -$37.3K
POOL icon
431
Pool Corp
POOL
$6.73B
– –
-7,724
Closed -$2.46M
PRCT icon
432
PUT
Procept Biorobotics
PRCT
$1.3B
– –
-15,000
Closed -$27.4K
PTGX icon
433
CALL
Protagonist Therapeutics
PTGX
$9.43B
– –
-20,000
Closed -$7.5K
RENE
434
DELISTED
Cartesian Growth Corp II
RENE
– –
-356,946
Closed -$4.24M
RENEW
435
DELISTED
Cartesian Growth Corporation II Warrant
RENEW
– –
-118,982
Closed -$7.4K
ROIV icon
436
Roivant Sciences
ROIV
$25.2B
– –
-42,819
Closed -$432K
RSG icon
437
Republic Services
RSG
$68.2B
– –
-88,200
Closed -$21.4M
SLN
438
Silence Therapeutics
SLN
$907M
– –
-62,639
Closed -$177K
STLD icon
439
Steel Dynamics
STLD
$34.7B
– –
-32,450
Closed -$4.06M
STRO icon
440
Sutro Biopharma
STRO
$333M
– –
-2,828
Closed -$18.4K
SWTX
441
PUT
DELISTED
SpringWorks Therapeutics
SWTX
– –
-45,000
Closed -$315K
TAL icon
442
TAL Education Group
TAL
$6.88B
– –
-37,000
Closed -$489K
TLT icon
443
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$46.6B
– –
-1,650,000
Closed -$1.68M
TPR icon
444
Tapestry
TPR
$24.4B
– –
-15,000
Closed -$1.06M
TRML
445
DELISTED
Tourmaline Bio
TRML
– –
-17,860
Closed -$272K
TSLA icon
446
Tesla
TSLA
$1.4T
– –
-2,500
Closed -$753K
TW icon
447
Tradeweb Markets
TW
$22.4B
– –
-15,000
Closed -$2.23M
VERU icon
448
Veru
VERU
$45M
– –
-10,102
Closed -$49.5K
VRNA
449
DELISTED
Verona Pharma
VRNA
– –
-17,150
Closed -$1.09M
YARW
450
Yarrow Bioscience
YARW
$80.7M
– –
-911
Closed -$72K
15 16 17
18
19

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q2 2025 Portfolio in Review

As of Q2 2025, UBS O'Connor held 480 positions worth $3.69B, down 13% from $4.23B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

UBS O'Connor withdrew a net $781M in Q2 2025, closing 113 positions and reducing 86 holdings. Its most notable exit was Discover Financial Services, an estimated $408M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 17% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, UBS O'Connor opened a new position in Skechers worth $227M.

  • UBS O'Connor's largest Q2 2025 buy was Skechers: 3,598,177 shares worth $227M.
  • UBS O'Connor added most to Blueprint Medicines in Q2 2025, an estimated $176M increase.
  • UBS O'Connor's biggest Q2 2025 reduction was Hess, cutting an estimated $251M.
  • UBS O'Connor fully exited Discover Financial Services in Q2 2025, selling an estimated $408M.
  • UBS O'Connor's ten largest holdings make up 57% of its $3.69B portfolio in Q2 2025.
  • UBS O'Connor opened 156 new positions and closed 113 in Q2 2025.
  • UBS O'Connor's portfolio value fell 13% quarter-over-quarter to $3.69B.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.